Compass Lexecon Adds Healthcare Economist Matthew Grennan
WASHINGTON, March 05, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the continued investment in the firm's subsidiary Compass Lexecon with the appointment of Matthew Grennan as an affiliate.
Dr. Grennan, who is based in Atlanta, is an Associate Professor of Economics at Emory University. He specializes in using empirical and theoretical industrial organization models to analyze competition and innovation in healthcare and life-science markets.
Dr. Grennan has served as an expert witness, providing verbal and written testimony in numerous high-profile healthcare matters. His work informs business strategy and policy debates regarding price transparency, relationships between physicians and industry, regulation of new products, and antitrust. He also examines how complex incentives and imperfect information affect how health technologies are developed, adopted and priced.
'The healthcare industry has experienced major disruptions over the last few years, from the COVID-19 pandemic and the rise of telemedicine to the implementation of new technologies,' said Daniel R. Fischel, Chairman of Compass Lexecon. 'Matthew adds great value to the firm in the healthcare economics and related fields and strengthens our top-notch roster of affiliates that can provide data-driven solutions to clients.'
Dr. Grennan is a Research Associate at the National Bureau of Economic Research and an Editor at the Journal of Political Economy Microeconomics. He has received research grants from the National Science Foundation and the National Institute for Health Care Management.
Commenting on his affiliation with Compass Lexecon, Dr. Grennan said, 'I look forward to collaborating with the Compass Lexecon team to provide the highest level of service to their clients navigating complex economic issues.'
About FTI Consulting
FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,300 employees in 34 countries and territories as of December 31, 2024. The Company generated $3.69 billion in revenues during fiscal year 2024. In certain jurisdictions, FTI Consulting's services are provided through distinct legal entities that are separately capitalized and independently managed. More information can be found at www.fticonsulting.com.
FTI Consulting, Inc.
555 12th Street NW
Washington, DC 20004
+1.202.312.9100
Investor Contact:
Mollie Hawkes
+1.617.747.1791
Media Contact:
Matthew Bashalany
+1.617.897.1545
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
19 minutes ago
- Epoch Times
Nasal, Baby Teething Swabs Recalled Nationwide Over Microbial Contamination Fears
New Jersey-based Church & Dwight Co., Inc. is recalling three nasal and baby teething swab products due to potential fungal contamination in the cotton swab components, the company said in a June 6 The recall is applicable to three products: Zicam Cold Remedy Nasal Swabs designed to tackle the common cold, Zicam Nasal AllClear Swabs used for cleansing, and Orajel Baby Teething Swabs aimed at soothing teething discomfort among toddlers and infants.
Yahoo
26 minutes ago
- Yahoo
Why Recursion Pharmaceuticals (RXRX) Soared On Friday
We recently published a list of . In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other Friday's best-performing stocks. Recursion Pharmaceuticals grew its share prices by 20.13 percent on Friday to close at $5.49 apiece following the unveiling of Boltz-2, touted as the next-generation AI model to predict binding affinity. According to Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX), the new model is powered by its NVIDIA supercomputer for its training and validation, and represents the next step beyond existing biomolecular structure prediction models like AlphaFold3 and its predecessor, Boltz-1. A pharmacist in a hospital pharmacy stands next to a row of various drug containers. 'Selecting the right molecules early is one of the most fundamental challenges in drug discovery, with implications for whether R&D programs succeed or fail,' said Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Chief Commercial Officer Najat Khan. 'By predicting both molecular structure and binding affinity simultaneously with unprecedented speed and scale, Boltz-2 gives R&D teams a powerful tool to triage more effectively and focus resources on the most promising compounds. Collaborations like this, bridging academic innovation and industry application, play an important role in advancing the field and, ultimately, improving how we develop and deliver medicines for patients,' she added. Overall, RXRX ranks 2nd on our list of Friday's best-performing stocks. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
an hour ago
- Business Wire
BF-A, BF-B Investors Have Opportunity to Join Brown-Forman Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Brown-Forman Corporation ('Brown-Forman' or 'the Company') (NYSE: BF-A, BF-B) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Brown-Forman reported its financial results for fiscal year 2025 on June 5, 2025. The Company reported a decline in year-over-year sales of 7.3% and earnings per share below consensus estimates. The Company stated its "results did not meet our long-term growth aspirations," and advised investors that "looking ahead to fiscal 2026, we expect continued headwinds." If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
